To improve patient health and well-being, Novartis medicines must have the complete confidence of those who prescribe and use them. As a corporate citizen, we are committed to this goal.

Patients and healthcare providers know that, beyond meeting regulatory requirements for product safety and efficacy, Novartis does everything possible to communicate concerns based on clinical trials and other research. Labels and package inserts often describe possible side effects and other risks, and provide directions for avoiding potential problems.

Novartis discloses data from our clinical trials, no matter what the outcome. We assess safety concerns throughout the development of our products.

Ensuring patient safety does not end at product approval. We continue to assess risks or safety signals that emerge when a product is on the market. We work to find new and better ways to identify problems and communicate them as clearly as possible.

Our pharmacovigilance programs quickly identify, address and communicate new adverse events to regulatory agencies, including the US Food and Drug Administration (FDA) and the European Agency for the Evaluation of Medicinal Products (EMEA), as well as to healthcare professionals and patients. We also work to protect patients from counterfeit products, which have created a growing concern around the world.

Responsible corporate citizenship is about open communication, going beyond the letter of the law and placing patients front and center in all our efforts. There is nothing more important than the safety of our products and those who use them.

Learn more about our commitment to patient safety on our corporate citizenship website